Next 10 |
home / stock / ghrs / ghrs articles
Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of...
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transf...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-...
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Au...
Biden To Decide On Psychedelic Therapy Bill President Joe Biden received the final version of a large-scale defense bill providing funding for psyc...
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary ...
Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for ...
News, Short Squeeze, Breakout and More Instantly...
GH Research PLC Company Name:
GHRS Stock Symbol:
NASDAQ Market:
2024-05-31 08:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-11 09:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in...